Clinical solution for accurate detection of lung cancer
Lung cancer is one of the most common malignant tumors in the world. Lung cancer ranks first in both morbidity and mortality worldwide. In China, there are about 828,000 new cases of lung cancer and about 715,000 deaths each year. According to histological classification, it can be divided into small cell lung cancer and non-small cell lung cancer. About 80% of lung cancer is non-small cell lung cancer, and about 75% of patients are already in the middle and late stages when diagnosed.
818
715
Mortality/No.1
Core driver genes of lung cancer and clinical value
|
First Generation |
Second Generation |
Three generations |
EGFR |
Gefitinib, Erlotinib, Ecatinib |
Afatinib, Dacotinib |
Axitinib, Amitinib, Fumatinib, etc |
KRAS |
Sotolabu, Adagrasibu |
||
BRAF |
Dabrafenib, Trametinib |
||
PIK3CA |
Mutations that affect the efficacy of EGFR-TKIs |
||
NRAS |
MEK inhibitors |
||
NTRK |
Larotrectinib、Entrectinib |
||
ALK |
Crizotinib |
Alectinib, Ceritinib
Brigatinib, Ensartinib
|
Lorlatinib |
ROS1 |
Crizotinib, ceritinib, lorlatinib, entrectinib |
||
HER2 |
DS-8201(trastuzumab deruxtecan, T-DXd), Pyrotinib |
||
MET |
Tepotinib, Capmatinib, Sirolimus, Gumetinib, etc. |
||
RET |
Selpercatinib、Pratinib |
Ordering Information
Workflow
Sample collection
Nucleic acid extraction, PCR system configuration and sample addition
Droplet generation and expansion